Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 17, 2013, Pages 5573-5582

  Hayat, Faisal ^a   Cho, Sungjin ^b   Rhim, Hyewhon ^b   Indu Viswanath, Ambily Nath ^b,c   Pae, Ae Nim ^b,c   Lee, Jae Yeol ^d   Choo, Dong Joon ^d   Choo, Hea Young Park ^a  

^a Ewha Womans University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

^d Kyung Hee University   (South Korea)

Author keywords

5 HT6 receptor antagonist 1 Amino 4 methylpiperazine; Pharmacophore mapping; QSAR; Sulfonyl indole 3D

Indexed keywords

(2 METHYL 1H INDOL 3 YL) N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; 1 AMINO 4 METHYLPIPERAZINE; 1 BENZENESULFONYL 5 METHOXY N,N DIMETHYLTRYPTAMINE; 5 [[3 [(4 METHYLPIPERAZIN 1 YLIMINO)METHYL] 2 METHYL 1H INDOL 1 YL]SULFONYL] N,N DIMETHYL(1,2 DIPHENYLDIAZENE) 1 AMINE; 5 [[[3 (4 METHYLPIPERAZIN 1 YLIMINO)METHYL] 2 METHYL 1H INDOL 1 YL]SULFONYL] N,N DIBUTYLNAPHTHALEN 1 AMINE; 5 [[[3 (4 METHYLPIPERAZIN 1 YLIMINO)METHYL] 2 METHYL 1H INDOL 1 YL]SULFONYL] N,N DIMETHYLNAPHTHALEN 1 AMINE; [1 (4 CHLOROBIPHENYLSULFONYL) 2 METHYL 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [1 (4 FLUOROPHENYLSULFONYL) 2 METHYL 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [1 (4 IODOPHENYLSULFONYL) 2 METHYL 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [1 (4 NITROPHENYLSULFONYL) 2 METHYL 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [1 (4 TOLYLSULFONYL) 2 METHYL 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [1 (5 CHLORO 2 METHOXY 4 METHYLPHENYLSULFONYL) 2 METHYL 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [1 [2 (NAPHTHALEN 1 YL)ETHYLSULFONYL] 2 METHYL 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [2 METHYL 1 (ARYLSULFONYL) 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [2 METHYL 1 (BIPHENYLSULFONYL) 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; [2 METHYL 1 (NAPHTHALENSULFONYL) 1H INDOL 3 YL] N (4 METHYLPIPERAZIN 1 YL)METHANIMINE; DIMEBON; E 6801; INDOLE; LIGAND; LU AE 58054; N (4 METHYLPIPERAZIN 1 YL) (2 PHENYL 1H INDOL 3 YL)METHANIMINE; N (4 METHYLPIPERAZIN 1 YL) [2 PHENYL 1 (ARYLSULFONYL) 1H INDOL 3 YL]METHANIMINE; PIPERAZINE DERIVATIVE; SB 258585; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN 6 RECEPTOR LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 181187;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; PHARMACOPHORE; PROTEIN TARGETING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYNTHESIS;

1-AMINO-4-METHYLPIPERAZINE; 3D QSAR; 5-HT(6) RECEPTOR ANTAGONIST; PHARMACOPHORE MAPPING; SULFONYL INDOLE;

ALGORITHMS; DRUG DESIGN; HEK293 CELLS; HUMANS; INDOLES; IONS; LIGANDS; PIPERAZINES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881376737     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.05.051     Document Type: Article

References (25)

1. J. Arnt, and C.K. Olsen Int. Rev. Neurobiol. 96 2011 141
2. D. Witty, M. Ahmed, and T.T. Chuang Prog. Med. Chem. 48 2009 163
3. K. Hirano, T.M. Piers, K.L. Searle, N.D. Miller, A.R. Rutter, and P.F. Chapman Life Sci. 84 2009 558
4. R. Emsley Expert Opin. Invest. Drugs 18 2009 1103
5. W.J. Gledenhuys, and C.J. Van der Schyf Curr. Top. Med. Chem. 8 2008 1035
6. K.C.F. Fone Neuropharmacology 55 2008 1015
7. J.S. Rodefer, T.N. Nguyen, J.J. Karlsson, and J. Arnt Neuropsychopharmacology 33 2008 2657
8. C.A. Jones, and A.C. McCreary Neuropharmacology 55 2008 1056
9. G. Perez-Garcia, and A. Meneses Behav. Brain Res. 195 2008 17
10. M.V. King, C.A. Marsden, and K.C. Fone Trends Pharmacol. Sci. 29 2008 482
11. D.J. Heal, S.L. Smith, A. Fisas, X. Codony, and H. Buschmann Pharmacol. Ther. 117 2008 207
12. C. Routledge, S.M. Bromidge, S.F. Moss, G.W. Price, W. Hirst, H. Newman, G. Riley, T. Gager, T. Stean, N. Upton, S.E. Clarke, A.M. Brown, and D.N. Middlemiss Br. J. Pharmacol. 130 2000 1606
13. G.G. Perez Pharmacol. Biochem. Behav. 81 2005 673
14. Kelly, M. G.; Cole, D. C. WO Patent 2,002,036,562, 2006.
15. Beard, C. C.; Clark, R. D.; Fisher, L. E.; Harris, R. N.; Repke, D. B. WO Patent 2,002,098,857, 2002.
16. Madera, A. M.; Weikert, R. J.; WO Patent 2,004,026,830, 2004.
17. Madera, A. M.; Weikert, R. J.; WO Patent 2,004,026,831, 2004.
18. M.L. Lopez-Rodriguez, B. Benhamu, T. de la Fuente, A. Sanz, L. Pardo, and M. Campillo J. Med. Chem. 48 2005 4216
19. R.A. Glennon J. Med. Chem. 46 2003 2795
20. J. Holenz, P.J. Pauwels, J.L. Diaz, R. Merce, X. Codony, and H. Buschmann Drug Discovery Today 11 2006 283
21. S.M. Bromidge Spec. Publ. R. Soc. Chem. 264 2001 101
22. K.G. Liu, and A.J. Robichaud Drug Dev. Res. 70 2009 145
23. K.G. Liu, J.R. Lo, T.A. Comery, G.M. Zhang, J.Y. Zhang, D.M. Kowal, D.L. Smith, E.H. Kerns, L.E. Schechter, and A.J. Robichaud Bioorg. Med. Chem. Lett. 19 2009 2413
24. W.K. Kroeze, K. Kristiansen, and B.L. Roth Curr. Top. Med. Chem. 2 2002 507
25. E. Euna Yoo, F. Hayat, H. Rhim, and H.-Y. Park Choo Bioorg. Med. Chem. 20 2012 2707